Andrew Grove, PhD

Job title:

Former Chairman

Organization:

Intel Corporation; PwP

Contributions:

Published Contributions:

Does the slope of UPDRS vs. time show neuroprotection?

response to: Results of ADAGIO trial for rasagiline suggest possible disease-modifying effect

13 Oct 2009 01:33 PM EST

Dr. Schwarzschild, I read your posting on PDOnlineResearch on Adagio, etc. with interest. I wonder if we are overlooking a fairly basic indicator of disease modification (nay, neuroprotection); ...

Responses: 2

Is it time to rethink infusion trial design?

response to: Surgical Delivery of Therapeutics

25 Aug 2009 12:41 PM EST

After two decades of painstaking work, pressure-driven infusion is emerging as drug delivery method of choice for introducing substances with large molecules into the brain parenchyma. Some ...